Merck's Biosimilar Version Of Lantus Tops Phase III Studies
Zacks Investment Research | Jun 14, 2016 06:14AM ET
Merck & Co. Inc. (NYSE:MRK) announced encouraging data from two phase III studies on its insulin glargine candidate, MK-1293, for the treatment of type I and type II diabetes.
The two randomized, active-controlled, open-label studies evaluated the safety and efficacy of MK-1293, in comparison to Sanofi’s (NYSE:SNY) Lantus (insulin glargine).
Data from the studies revealed that MK-1293 demonstrated non-inferiority in change from baseline A1C (average blood glucose) and had a similar safety profile as Lantus after 24 weeks in patients with type I and type II diabetes, thereby achieving the primary endpoint. In addition, the studies met the pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, thereby establishing that the investigational treatment was similar, within a certain range, to the current therapy.
Results were presented at the Scientific Sessions of the American Diabetes Association.
Merck is developing MK-1293 in collaboration with Samsung (KS:005930) Bioepis. Under the agreement terms, Merck is responsible for clinical development, manufacturing and commercialization while Bioepis is partially funding development.
Currently, an application for regulatory approval of MK-1293 for the treatment of patients with type I and type II diabetes is under review in the EU. The company expects to submit a regulatory filing for the candidate in the U.S. this year.
We note that the diabetes market is heavily crowded and several companies are working on bringing new and improved treatments to market.
We remind investors that Eli Lilly and Company (NYSE:LLY) is already marketing a biosimilar version of Lantus in the EU, which is expected to hit U.S. markets after Dec 15, 2016.
Merck currently carries a Zacks Rank #3 (Hold). Bristol-Myers Squibb Co. (NYSE:BMY) , with a Zacks Rank #1 (Strong Buy), is a better-ranked stocks in the health care sector.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.